10 Big Names Feasting on Gains Ahead of Thanksgiving

1. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals soared to a new three-year high on Wednesday, as investors took heart from its impressive earnings performance for the full fiscal year, alongside the Food and Drug Administration’s (FDA) approval for its treatment for familial chylomicronemia syndrome (FCS).

At intra-day trading, the stock soared to as high as $59.15 before trimming gains to end the day just up by 23.34 percent at $57.71 apiece.

In an updated report on the same day, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) said it narrowed its attributable net loss by 99.7 percent to only $1.63 million from the $599.49 million last year, as revenues soared by 23,585 percent to $829.4 million from $3.5 million year-on-year.

Additionally, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) recently secured the approval of the FDA to sell redemplo following positive clinical trial results. Redemplo is the first and only approved siRNA medicine to reduce triglycerides in adults with FCS.

Following the approval, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is targeting to start selling redemplo before the end of the year.

FCS is a severe and rare disease, affecting as many as 6,500 people in the US. The disease is characterized by triglyceride levels that can be 10 to 100 times higher than normal, leading to a substantially higher risk of developing acute, recurrent, and potentially fatal pancreatitis.

While we acknowledge the potential of ARWR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARWR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.